PPGN PolyPeptide Group AG
44.05CHF-0.11%Mkt Cap: 1.66B $P/E: 107.44Today
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceut…
Industry Peers
Drug Manufacturers - Specialty & Generic$64.30BUSDP/E 25.0
$57.06BUSD
$46.10BUSDP/E 65.9
$38.70BUSDP/E 18.3
$28.27BUSDP/E 12.1
$28.80BUSDP/E 11.4
$23.23BUSDP/E 19.4
$20.22BUSD
$14.14BUSDP/E 110.6
$14.55BUSDP/E 21.0
$12.60BUSDP/E 22.8
$11.06BUSD
$10.20BUSDP/E 29.2
$8.59BUSDP/E 19.2
$7.07BUSDP/E 42.3
$7.00BUSDP/E 109.9
$6.77BUSD
$6.53BUSDP/E 23.9
$5.83BUSDP/E 76.6
$4.21BUSDP/E 12.8
| Headline | Source | Time |
|---|---|---|
Older | ||
PolyPeptide Group AG (PLYGF) (H1 2026) Earnings Call Highlights: Revenue Surges 41. ... PolyPeptide Group AG (PLYGF) upgrades 2026 guidance amid strong metabolic drug demand and a proposed acquisition by Samsung Biologics. | ||
 Samsung Biologics to acquire PolyPeptide in $1.81bn cash deal Completion of the deal is anticipated towards the end of 2026. | ||